Evidence map›Paper›PMID 34698976›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2022

Quality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway.

Nataliia Moshina, Ragnhild S Falk, Edoardo Botteri, Marthe Larsen, Lars A Akslen, John A Cairns, Solveig Hofvind

Erratum issued Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03877029 (Long-term Effects Following Treatment of Women With Screen-detected Versus Symptomatic Breast Cancer), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03877029 completednot on this map

Long-term Effects Following Treatment of Women With Screen-detected Versus Symptomatic Breast Cancer

TypeobservationalSponsorNorwegian Institute of Public HealthRan2019 to 2025Enrolled4,487ConditionsBreast Cancer
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Quality of life of women with a screen-detected versus clinically detected breast cancer in the Netherlands: a prospective cohort study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Nataliia MoshinaCancer Registry of Norway, Majorstuen, P.O. 5313, 0304, Oslo, Norway. namo@kreftregisteret.no.ORCID http://orcid.org/0000-0003-1477-1968
Ragnhild S FalkOslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.
Edoardo BotteriCancer Registry of Norway, Oslo, Norway.
Marthe LarsenCancer Registry of Norway, Majorstuen, P.O. 5313, 0304, Oslo, Norway.
Lars A AkslenCentre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway.
John A CairnsDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
Solveig HofvindCancer Registry of Norway, Majorstuen, P.O. 5313, 0304, Oslo, Norway.
Cancer Registry of Norway · NOHaukeland University Hospital · NOLondon School of Hygiene & Tropical Medicine · GBOslo University Hospital · NO

Funding

Stiftelsen Dam N 2019/FO244363
6 · The paper itself

Abstract

purposeBreast cancers detected at screening need less aggressive treatment compared to breast cancers detected due to symptoms. The evidence on the quality of life associated with screen-detected versus symptomatic breast cancer is sparse. This study aimed to compare quality of life among Norwegian women with symptomatic, screen-detected and interval breast cancer, and women without breast cancer and investigate quality adjusted life years (QALYs) for women with breast cancer from the third to 14th year since diagnosis.

methodsThis retrospective cross-sectional study was focused on women aged 50 and older. A self-reported questionnaire including EQ-5D-5L was sent to 11,500 women. Multivariable median regression was used to analyze the association between quality of life score (visual analogue scale 0-100) and detection mode. Health utility values representing women's health status were extracted from EQ-5D-5L. QALYs were estimated by summing up the health utility values for women stratified by detection mode for each year between the third and the 14th year since breast cancer diagnosis, assuming that all women would survive.

resultsAdjusted regression analyses showed that women with screen-detected (n = 1206), interval cancer (n = 1005) and those without breast cancer (n = 1255) reported a higher median quality of life score using women with symptomatic cancer (n = 1021) as reference; 3.7 (95%CI 2.2-5.2), 2.3 (95%CI 0.7-3.8) and 4.8 (95%CI 3.3-6.4), respectively. Women with symptomatic, screen-detected and interval cancer would experience 9.5, 9.6 and 9.5 QALYs, respectively, between the third and the 14th year since diagnosis.

conclusionWomen with screen-detected or interval breast cancer reported better quality of life compared to women with symptomatic cancer. The findings add benefits of organized mammographic screening.

Indexed as

Breast NeoplasmsQuality of LifeAgedCross-Sectional StudiesFemaleHealth StatusHumansMiddle AgedRetrospective StudiesSurveys and QuestionnairesBreast cancer screeningEQ-5D-5LInterval breast cancerQuality of lifeSymptomatic breast cancer

Identifiers

PMID34698976
PMCPMC8547129
OpenAlexW3209249397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.